Abstract
In their article entitled “Demonstration of Efficacy in the Treatment of Dry Eye Disease with 0.18% Sodium Hyaluronate Ophthalmic Solution (Vismed, Rejena),” the authors claim in the discussion section that so far, in the United States, no drug has gained Food and Drug Administration (FDA) approval for the treatment of dry eye disease (DED). 1 Vogel R. Crockett R.S. Oden N. Laliberte T.W. Molina L. Sodium Hyaluoronate Ophthalmic Study GroupDemonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (Vismed, Rejena). Am J Ophthalmol. 2010; 149: 594-601 Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar Demonstration of Efficacy in the Treatment of Dry Eye Disease with 0.18% Sodium Hyaluronate Ophthalmic Solution (Vismed, Rejena)American Journal of OphthalmologyVol. 149Issue 4PreviewTo evaluate the efficacy and safety of 0.18% sodium hyaluronate ophthalmic solution (Rejena, Vismed) compared with its vehicle for the treatment of signs and symptoms of dry eye disease. Full-Text PDF ReplyAmerican Journal of OphthalmologyVol. 150Issue 5PreviewFirst, I would like to quote correctly the sentence under debate in the referenced article: “Although more than 20 drug products have undergone clinical testing in the United States for the treatment of dry eye disease, no product has been approved for this indication.”1 Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
